Xp22.2-3 Loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer

Gynecologic Oncology

Volumn 76, Issue 3, 2000, Pages 418-422

  Buekers, Thomas E ^a   Lallas, Thomas A ^a   Buller, Richard E ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

BRCA1 mutation; Loss of heterozygosity; Ovarian cancer; X chromosome; X chromosome inactivation

Indexed keywords

MICROSATELLITE DNA;

ARTICLE; CHROMOSOME XP; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HETEROZYGOSITY LOSS; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; X CHROMOSOME INACTIVATION;

EID: 0034016186     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5713     Document Type: Article

References (19)

1. Buekers T E, Buller R E. The prognostic significance of X chromosome inactivation in ovarian cancer. CME J Gynecol Oncol. 4:1999;186-188.
2. Buller R E, Sood A K, Lallas T, Buekers T, Skilling J. Non-random X-chromosome inactivation in germline ovarian cancer DNA is associated with BRCA1 mutation. J Natl Cancer Inst. 91:1999;339-346.
3. Buller R E, Skilling J S, Kaliszewski S, Niemann T, Anderson B. Absence of significant germline p53 mutations in ovarian cancer patients. Gynecol Oncol. 58:1995;368-374.
4. Skilling J S, Powills K, Lager D J, Anderson B, Sorosky J, Buller R E. p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: Lack of correlation with familial and clinical factors. Gynecol Oncol. 61:1996;180-188.
5. Nelson D L, Ballabio A, Cremers F, Monaco A P, Schlessinger D. Report of the sixth international workshop on X chromosome mapping 1995. Cytogenet Cell Genet. 71:1995;308-335.
6. Nagaraja R, MacMillan S, Kerr J, Jones C, Griffin S, Schmatz M, Terrell J, Shomaker M, Jermak C, Hott C, Masisi M, Mumm S, Srivastava A, Pilia G, Featherstone T, Mazzarella R, Kesterson S, McCauley B, Railey B, Burough F, Nowotny V, D'Urso M, States D, Brownstein B, Schlessinger D. X chromosome map at 75-kb STS resolution, revealing extremes of recombination and GC content. Genome Res. 7:1997;210-222.
7. Pergolizzi R G, Erster S H, Goonewardena P, Brown W T. Detection of full fragile X mutation. Lancet. 339:1992;271-272.
8. Chevenix-Trench G, Kerr J, Hurst T, Yang-Chia S, Purdie D, Bergman L, Friedlander M, Sanderson B, Zournazi A, Coombs T, Leary J A, Crawford E, Shelling A N, Cooke I, Ganesan T S, Searle J, Choi C, Barrett J C, Khoo S K, Ward B. Analysis of loss of heterozygosity and Kras2 mutations in ovarian neoplasms: Clinicopathologic correlations. Genes Chrom Cancer. 18:1997;75-83.
9. Edelson M I, Lau C C, Colitti C V, Welch W R, Bell D A, Berkowitz R S, Mok S C. A one centiMorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive ovarian tumors. Oncogene. 16:1998;197-202.
10. Yang-Feng T L, Li S, Han H, Schwartz P E. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer. 52:1992;575-580.
11. Yang-Feng Tl, Han H, Chen K C, Li S B, Claus E B, Carcangiu M L, Chambers S K, Chambers J T, Schwartz P E. Allelic loss in ovarian cancer. Int J Cancer. 54:1993;546-551.
12. Lallas T A, Buekers T E, Buller R E. BRCA1 mutations in familial ovarian cancer. Mol Gen Metab. 67:1999;357-363.
13. Brown C J, Willard H F. Localization of a gene that escapes inactivation to the X chromosome proximal short arm: Implications for X inactivation. Am J Hum Genet. 46:1990;273-279.
14. Sood A K, Buller R E. Genomic instability in ovarian cancer: A reassessment using arbitrarily primed polymerase chain reaction. Oncogene. 13:1996;2499-2504.
15. Chen, J, J, Silver, D, Cantor, S, Livingston, D, M, Scully, R, BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 59:1752S- 1756S.
16. Osbourne R J, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer. 69:1994;429-438.
17. Choi C, Cho S, Horikawa I, Berchuck A, Wang N, Cedrone E, Jhung S W, Lee J B, Kerr J, Chevenix-Trench G, Kim S, Barrett J C, Koi M. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. Genes Chrom Cancer. 20:1997;234-242.
18. Zhang H, Tombline G, Weber B L. BRCA1, BRCA2, and DNA damage response: Collision or collusion. Cell. 92:1998;433-436.
19. Jensen D E, Proctor M, Marquis S T, Gardner H P, Ha S I, Chodosh L A, Ishov A M, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz D C, Wilkinson K D, Maul G G, Barlev N, Berger S L, Prendergrast G C, Rauscher F J. BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 16:1998;1097-1112.